APA (7th ed.) Citation

AA, M., CF, A., DM, C., LD, R., M, M., M, E., . . . G, G. (2025). Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: A nationwide register-based cohort study. Cardiovascular diabetology, 24(1), 314. https://doi.org/10.1186/s12933-025-02871-w

Chicago Style (17th ed.) Citation

AA, Mohamed, et al. "Erythrocytosis Incidence and Thromboembolic Risk in Heart Failure with Reduced Ejection Fraction Treated with SGLT2 Inhibitors: A Nationwide Register-based Cohort Study." Cardiovascular Diabetology 24, no. 1 (2025): 314. https://doi.org/10.1186/s12933-025-02871-w.

MLA (9th ed.) Citation

AA, Mohamed, et al. "Erythrocytosis Incidence and Thromboembolic Risk in Heart Failure with Reduced Ejection Fraction Treated with SGLT2 Inhibitors: A Nationwide Register-based Cohort Study." Cardiovascular Diabetology, vol. 24, no. 1, 2025, p. 314, https://doi.org/10.1186/s12933-025-02871-w.